We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+30.52%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.74B
AUM Growth
+$261M
Cap. Flow
-$277M
Cap. Flow %
-10.08%
Top 10 Hldgs %
32.74%
Holding
95
New
12
Increased
24
Reduced
31
Closed
21

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$88.4M
2
UTHR icon
United Therapeutics
UTHR
+$54.7M
3
CVS icon
CVS Health
CVS
+$52.7M
4
AVTR icon
Avantor
AVTR
+$43.5M
5
ABBV icon
AbbVie
ABBV
+$41.5M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$60.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$54.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$44.3M
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$42.1M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$38.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.29%
2 Miscellaneous 4.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
1
Arvinas
ARVN
$600M
$123M 4.48%
2,985,117
+370,157
+14% +$8.65M
BSX icon
2
Boston Scientific
BSX
$67.9B
$109M 3.98%
1,890,000
-175,800
-9% -$9.38M
CI icon
3
CALL
Cigna
CI
$73.7B
$105M 3.82%
+350,000
New +$102M
TMO icon
4
Thermo Fisher Scientific
TMO
$230B
$96.9M 3.53%
+182,600
New +$88.4M
ACHC icon
5
Acadia Healthcare
ACHC
$2.66B
$89.9M 3.28%
1,156,692
+441,692
+62% +$32.7M
NBIX icon
6
Neurocrine Biosciences
NBIX
$15.7B
$86.7M 3.16%
658,000
+5,900
+0.9% +$679K
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.74B
$85.4M 3.11%
3,950,000
+1,129,000
+40% +$17.4M
NTRA icon
8
Natera
NTRA
$47B
$69.5M 2.53%
1,110,000
+211,000
+23% +$10.5M
DHR icon
9
Danaher
DHR
$152B
$67.1M 2.45%
290,000
+90,795
+46% +$19.3M
THC icon
10
Tenet Healthcare
THC
$21.5B
$65.8M 2.4%
871,000
-92,800
-10% -$5.88M
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$65.2M 2.38%
206,000
-80,700
-28% -$15.7M
FUSN
12
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$62.5M 2.28%
6,500,328
+718,478
+12% +$3.49M
JAZZ icon
13
Jazz Pharmaceuticals
JAZZ
$15.9B
$60.2M 2.19%
489,119
-308,381
-39% -$38.5M
REGN icon
14
Regeneron Pharmaceuticals
REGN
$81.8B
$59.7M 2.18%
68,000
+10,000
+17% +$8.23M
CVS icon
15
CVS Health
CVS
$119B
$58.4M 2.13%
+740,000
New +$52.7M
BPMC
16
DELISTED
Blueprint Medicines
BPMC
$56.7M 2.07%
615,000
-136,600
-18% -$8.85M
IMGN
17
DELISTED
Immunogen Inc
IMGN
$54.2M 1.98%
1,829,215
-88,692
-5% -$1.77M
IDYA icon
18
IDEAYA Biosciences
IDYA
$3.87B
$54.1M 1.97%
1,520,000
-624,971
-29% -$18.7M
UTHR icon
19
United Therapeutics
UTHR
$22.1B
$52.2M 1.9%
+237,202
New +$54.7M
RCKT icon
20
Rocket Pharmaceuticals
RCKT
$424M
$51.5M 1.88%
1,719,103
+131,674
+8% +$2.91M
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$50.9M 1.85%
710,000
-91,100
-11% -$5.24M
LLY icon
22
Eli Lilly
LLY
$1.05T
$49.5M 1.81%
85,000
+10,000
+13% +$5.84M
BHVN icon
23
Biohaven
BHVN
$2.33B
$49.1M 1.79%
1,148,308
-137,092
-11% -$4.26M
AVTR icon
24
Avantor
AVTR
$9.86B
$48.4M 1.77%
+2,121,844
New +$43.5M
ZTS icon
25
Zoetis
ZTS
$32B
$47.4M 1.73%
240,000
-22,100
-8% -$3.91M
1
2 3 4

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q4 2023 Portfolio in Review

As of Q4 2023, Avidity Partners Management held 95 positions worth $2.74B, up 11% from $2.48B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $277M in Q4 2023, closing 21 positions and reducing 31 holdings. Its most notable exit was Cigna, an estimated $60.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Avidity Partners Management opened a new position in Thermo Fisher Scientific worth $96.9M.

  • Avidity Partners Management's largest Q4 2023 buy was Thermo Fisher Scientific: 182,600 shares worth $96.9M.
  • Avidity Partners Management added most to Structure Therapeutics in Q4 2023, an estimated $33.2M increase.
  • Avidity Partners Management's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $38.5M.
  • Avidity Partners Management fully exited Cigna in Q4 2023, selling an estimated $60.7M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.74B portfolio in Q4 2023.
  • Avidity Partners Management opened 12 new positions and closed 21 in Q4 2023.
  • Avidity Partners Management's portfolio value rose 11% quarter-over-quarter to $2.74B.

Based on Avidity Partners Management's 13F filing for Q4 2023, filed 14 Feb 2024.